Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1396175 | 0.78 | GABRA1 (0.32) | GABRA1GABRB2 | |
| SCHEMBL8622898 | 0.75 | HTR6 (0.40) | GABRA1GABRB2HTR6TOP2A | |
| SCHEMBL4565339 | 0.70 | KMT2A (0.47) | GABRA1GABRB2ALDH1A1TSHRMAPK1 | |
| SCHEMBL8951774 | 0.70 | HTR6 (0.38) | GABRA1GABRB2HTR6TOP2A | |
| SCHEMBL3764804 | 0.68 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL9323927 | 0.68 | GABRA1 (0.40) | GABRA1GABRB2ALDH1A1HSD17B10 | |
| SCHEMBL11819501 | 0.67 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL16447706 | 0.66 | HSD17B10 (0.37) | ALDH1A1TSHRHSD17B10 | |
| SCHEMBL10915787 | 0.66 | KDM4E (0.31) | ALDH1A1TSHRMAPK1ATMHSD17B10 | |
| SCHEMBL4785447 | 0.64 | MAPT (0.40) | GABRA1GABRB2ALDH1A1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2658835-B1 | OLEFIN OLIGOMERIZATION CATALYSTS AND METHODS OF MAKING AND USING SAME | CHEVRON PHILLIPS CHEMICAL CO (US) | 2016-08-17 | — | — | EP | disclosed |
| CN-103270006-B | Its method of olefin oligomerization catalyzer and preparation and use | Chevron Phillips Chemical Co.,L.P. (US) | 2016-04-27 | — | — | CN | disclosed |
| EP-2044093-B1 | OLEFIN OLIGOMERIZATION CATALYSTS AND METHODS OF USING SAME | CHEVRON PHILLIPS CHEMICAL CO (US) | 2014-12-03 | — | — | EP | disclosed |
| EP-2289901-B1 | Olefin oligomerization catalysts and methods of using same | CHEVRON PHILLIPS CHEMICAL CO (US) | 2014-07-09 | — | — | EP | disclosed |
| EP-2658835-A1 | OLEFIN OLIGOMERIZATION CATALYSTS AND METHODS OF MAKING AND USING SAME | Chevron Phillips Chemical Company LP (US) | 2013-11-06 | — | — | EP | disclosed |
| US-8334420-B2 | Selectivity for hexene and octene from ethylene; polymerization inhibitor containing chromium, titanium and vanadium | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120172645-A1 | Olefin Oligomerization catalysts and Methods of Making and Using Same | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2012092415-A1 | OLEFIN OLIGOMERIZATION CATALYSTS AND METHODS OF MAKING AND USING SAME | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2012-07-05 | — | — | WO | disclosed |
| EP-2289901-A1 | Olefin oligomerization catalysts and methods of using same | Chevron Phillips Chemical Company LP (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-2287172-A1 | Olefin oligomerization catalysts and methods of using same | Chevron Phillips Chemical Company LP (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-2044093-A2 | OLEFIN OLIGOMERIZATION CATALYSTS AND METHODS OF USING SAME | Chevron Phillips Chemical Company LP (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20080207857-A1 | Olefin Oligomerization Catalysts and Methods of Using Same | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2008-08-28 | — | — | US | disclosed |
| US-7378537-B2 | Olefin oligomerization catalysts and methods of using same | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2008-05-27 | — | — | US | disclosed |
| WO-2008014139-A2 | OLEFIN OLIGOMERIZATION CATALYSTS AND METHODS OF USING SAME | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080027188-A1 | OLEFIN OLIGOMERIZATION CATALYSTS AND METHODS OF USING SAME | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172645-A1 | Olefin Oligomerization catalysts and Methods of Making and Using Same | COG7, COG8, COG4 | GABRA1 3705/4885GABRB2 4182/4885HTR6 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.